Shares of JAN (NYSE:JAN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $29.1538.
Several analysts recently weighed in on JAN shares. Scotiabank cut their price target on JAN from $30.00 to $29.00 and set a “sector outperform” rating on the stock in a research note on Thursday, June 18th. Wells Fargo & Company upped their price target on JAN from $27.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Raymond James Financial started coverage on JAN in a research note on Tuesday, June 16th. They issued a “strong-buy” rating and a $34.00 price target on the stock. BNP Paribas Exane began coverage on JAN in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $27.00 price target on the stock. Finally, UBS Group set a $29.00 price objective on JAN in a research report on Thursday, June 18th.
Check Out Our Latest Research Report on JAN
JAN Price Performance
JAN (NYSE:JAN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.23 earnings per share for the quarter, hitting the consensus estimate of $0.23. The company had revenue of $200.35 million during the quarter, compared to analysts’ expectations of $157.96 million. JAN has set its FY 2026 guidance at 0.930-0.970 EPS.
JAN Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Friday, June 12th were given a $0.1599 dividend. The ex-dividend date of this dividend was Friday, June 12th. This represents a $0.64 annualized dividend and a yield of 2.3%.
JAN News Roundup
Here are the key news stories impacting JAN this week:
- Neutral Sentiment: Matinas BioPharma (MTNB) received a NYSE American non-compliance notice for insufficient stockholders’ equity, but the exchange accepted its compliance plan and granted it until October 2, 2027 to regain listing standards. Article: Matinas BioPharma Receives NYSE American Notice of Non-Compliance, Granted Plan Period to Regain Listing Standards
- Neutral Sentiment: JAN recently reported EPS in line with estimates and revenue that beat forecasts, which supports the longer-term fundamental case even as the stock has been volatile.
JAN Company Profile
Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025.
Read More
- Five stocks we like better than JAN
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for JAN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JAN and related companies with MarketBeat.com's FREE daily email newsletter.
